These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 28513286)

  • 1. Azelnidipine is a useful medication for the treatment of heart failure preserved ejection fraction.
    Kiuchi S; Hisatake S; Kabuki T; Oka T; Dobashi S; Fujii T; Ikeda T
    Clin Exp Hypertens; 2017; 39(4):350-354. PubMed ID: 28513286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Switching from Cilnidipine to Azelnidipine on Cardiac Sympathetic Nerve Function in Patients with Heart Failure Preserved Ejection Fraction.
    Kiuchi S; Hisatake S; Kabuki T; Oka T; Dobashi S; Fujii T; Ikeda T
    Int Heart J; 2018 Jan; 59(1):120-125. PubMed ID: 29269711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical study with azelnidipine in patients with essential hypertension. Antiarteriosclerotic and cardiac hypertrophy-inhibitory effects and influence on autonomic nervous activity.
    Nada T; Nomura M; Koshiba K; Kawano T; Mikawa J; Ito S
    Arzneimittelforschung; 2007; 57(11):698-704. PubMed ID: 18193691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma renin activity and aldosterone concentration are not altered by the novel calcium channel antagonist, azelnidipine, in hypertensive patients.
    Kondo T; Goto R; Sonoda K; Yasuda T; Ono K; Takaki Y; Yatsuda R; Miyamura N; Araki E
    Intern Med; 2010; 49(7):637-43. PubMed ID: 20371952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical usefulness of a dual L/N-type Ca2+ channel blocker, cilnidipine, in patients with chronic heart failure: assessment with 123I-MIBG myocardial scintigraphy].
    Ito K; Sugihara H; Nishikawa S; Adachi Y; Kato S; Azuma A; Matsubara H
    Kaku Igaku; 2003 Nov; 40(4):421-30. PubMed ID: 14733106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of cilnidipine on sympathetic nerve activity and cardiorenal function in hypertensive patients with type 2 diabetes mellitus: association with BNP and aldosterone levels.
    Tanaka M; Sekioka R; Nishimura T; Ichihara A; Itoh H
    Diabetes Res Clin Pract; 2014 Dec; 106(3):504-10. PubMed ID: 25458339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin-II receptor antagonist combined with calcium channel blocker or diuretic for essential hypertension.
    Ishimitsu T; Numabe A; Masuda T; Akabane T; Okamura A; Minami J; Matsuoka H
    Hypertens Res; 2009 Nov; 32(11):962-8. PubMed ID: 19696778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential effects of azelnidipine and amlodipine on sympathetic nerve activity in patients with primary hypertension.
    Inomata J; Murai H; Kaneko S; Hamaoka T; Ikeda T; Kobayashi D; Usui S; Furusho H; Sugiyama Y; Takata S; Takamura M
    J Hypertens; 2014 Sep; 32(9):1898-904. PubMed ID: 24979307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of new calcium channel blocker, azelnidipine, and amlodipine on baroreflex sensitivity and ambulatory blood pressure.
    Eguchi K; Tomizawa H; Ishikawa J; Hoshide S; Fukuda T; Numao T; Shimada K; Kario K
    J Cardiovasc Pharmacol; 2007 Jun; 49(6):394-400. PubMed ID: 17577104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The combination of OLmesartan and a CAlcium channel blocker (azelnidipine) or candesartan and a calcium channel blocker (amlodipine) in type 2 diabetic hypertensive patients: the OLCA study.
    Daikuhara H; Kikuchi F; Ishida T
    Diab Vasc Dis Res; 2012 Oct; 9(4):280-6. PubMed ID: 22718810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of azelnidipine on uric acid metabolism in patients with essential hypertension.
    Miyazaki S; Hamada T; Hirata S; Ohtahara A; Mizuta E; Yamamoto Y; Kuwabara M; Nosaka Y; Igawa O; Ogino K; Kato M; Yoshida A; Ninomiya H; Cheng J; Moriwaki Y; Yamamoto K; Hisatome I
    Clin Exp Hypertens; 2014; 36(7):447-53. PubMed ID: 24433018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of azelnidipine treatment on left ventricular diastolic performance in patients with hypertension and mild diastolic dysfunction: multi-center study with echocardiography.
    Ito H; Ishii K; Iwakura K; Nakamura F; Nagano T; Takiuchi S
    Hypertens Res; 2009 Oct; 32(10):895-900. PubMed ID: 19680260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Azelnidipine and glucose tolerance: possible indications and treatment selection for hypertensive patients with metabolic disorders.
    Shimada K; Miyauchi K; Daida H
    Expert Rev Cardiovasc Ther; 2015 Jan; 13(1):23-31. PubMed ID: 25434474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of calcium channel blockers on glucose tolerance, inflammatory state, and circulating progenitor cells in non-diabetic patients with essential hypertension: a comparative study between azelnidipine and amlodipine on glucose tolerance and endothelial function--a crossover trial (AGENT).
    Fukao K; Shimada K; Hiki M; Kiyanagi T; Hirose K; Kume A; Ohsaka H; Matsumori R; Kurata T; Miyazaki T; Daida H
    Cardiovasc Diabetol; 2011 Sep; 10():79. PubMed ID: 21906391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. L/N-type calcium channel blocker cilnidipine added to renin-angiotensin inhibition improves ambulatory blood pressure profile and suppresses cardiac hypertrophy in hypertension with chronic kidney disease.
    Kanaoka T; Tamura K; Wakui H; Ohsawa M; Azushima K; Uneda K; Kobayashi R; Fujikawa T; Tsurumi-Ikeya Y; Maeda A; Yanagi M; Toya Y; Umemura S
    Int J Mol Sci; 2013 Aug; 14(8):16866-81. PubMed ID: 23959116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hemodynamic influences of azelnidipine, a novel calcium channel blocker, on cerebral circulation in hypertensive patients with ischemic white matter lesions.
    Kimura Y; Kitagawa K; Oku N; Kajimoto K; Kato H; Tanaka M; Sakaguchi M; Hougaku H; Sakoda S; Hatazawa J
    Hypertens Res; 2008 Dec; 31(12):2147-54. PubMed ID: 19139604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in left ventricular relaxation after azelnidipine treatment in hypertensive patients with diabetes: subanalysis of a prospective single-arm multicentre study.
    Iwakura K; Ito H; Ishii K; Date M; Nakamura F; Nagano T; Takiuchi S;
    BMJ Open; 2014 Sep; 4(9):e006136. PubMed ID: 25270860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Azelnidipine reduces urinary protein excretion and urinary liver-type fatty acid binding protein in patients with hypertensive chronic kidney disease.
    Nakamura T; Sugaya T; Kawagoe Y; Suzuki T; Ueda Y; Koide H; Inoue T; Node K
    Am J Med Sci; 2007 Jun; 333(6):321-6. PubMed ID: 17570983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitory effects of azelnidipine tablets on morning hypertension.
    Kario K; Sato Y; Shirayama M; Takahashi M; Shiosakai K; Hiramatsu K; Komiya M; Shimada K
    Drugs R D; 2013 Mar; 13(1):63-73. PubMed ID: 23512719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of amlodipine and cilnidipine on cardiac sympathetic nervous system and neurohormonal status in essential hypertension.
    Sakata K; Shirotani M; Yoshida H; Nawada R; Obayashi K; Togi K; Miho N
    Hypertension; 1999 Jun; 33(6):1447-52. PubMed ID: 10373231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.